The first experience of using synthetic Antithrombin-III (Athenativ) in cardiosurgical practice

  • V. Dehtiar Ukrainian Children’s Cardiac Center (Kyiv)
  • O. Boichenko Ukrainian Children’s Cardiac Center (Kyiv)
  • V. Zhovnir Ukrainian Children’s Cardiac Center (Kyiv)
  • N. Chanhli Ukrainian Children’s Cardiac Center (Kyiv)
Keywords: antithrombin-III, cardiopulmonary bypass, heparin, activated coagulation time


Nowadays, the main share of heart surgery performed under artificial circulation, accompanied by a violation of hemostasis. Deficit antithrombin III is 0.02–1% of the population. The main clinical manifestation of deficiency of antithrombin III is thrombosis. The work conducted its own study of communication between levels of antithrombin-III and the result of the activated clotting time during cardiopulmonary bypass in cardiac practice.

Demonstrated that the quantitative and/or qualitative deficiency of antithrombin-III results in early postoperative complications and disorders in the hemostatic system.

During 2016 at the GI «Scientific-Practical Children`s Cardiac Center» an analysis of 11 patients, average age amounted to 50,2±27,2 years. In 5 (45.4%) patients were available concomitant diseases, in 4 (36.4%) patients – infective endocarditis, in 1 (9%) – HCV. The level of antithrombin-III in the study group amounted to 87.5% in patients with existing co-morbidities – 110.4%, indicating a qualitative deficiency of antithrombin-III in patients with concomitant infectious disease. Averages activated coaghulation time in patients formed the study group 352,4±18,6 seconds after the introduction of additional synthetic antithrombin-III under artificial circulation it reached 535±77 s.

We recommend using empirical synthetic antithrombin-III cardiac patients with AСT less than 400 seconds for the exclusion of intraoperative complications such as thrombosis.


1. Antithrombin III for critically ill patients: a systematic review with meta-analysis and trial sequential analysis / Allingstrup Mikkel, Wetterslev Jшrn, Ravn Frederikke B. et al. // Intensive Care Medicine. – 9 February 2016. – Vol. 42 (4). – P. 505–520.

2. Bical O. M. Comparison of the inflammatory response between miniaturized and standard CPB circuits in aortic valve surgery / O. M. Bical, Y. Fromes, D. Gaillard et al. // Eur. J. Cardiothorac. Surg. – 2006. – Vol. 29, № 5. – P. 699–702.

3. Burkhart C. S. Modifiable and nonmodifiable risk factors for postoperative delirium after cardiac surgery with cardiopulmonary bypass / C. S. Burkhart, S. Dell-Kuster, M. Gamberini et al. // J. Thorac. Cardiovasc. Surg. – 2010. – Vol. 24. – P. 555–559.

4. Antithrombin concentrate use in children receiving unfractionated heparin for acute thrombosis / Diaz R., Moffett B. S., Karabinas S. et al. // J Pediatr. – 2015. – Vol. 167. – P. 645–649.

5. Finley Alan, Greenberg Charles. Review article: heparin sensitivity and resistance: management during cardiopulmonary bypass // Anesthesia and analgesia. – 2013-06-01. – Vol. 6. – P. 1210–1222.

6. A randomized, controlled, multicenter trial of the effects of antithrombin on disseminated intravascular coagulation in patients with sepsis / Gando S., Saitoh D., Ishikura H. et al. // Critical Care. – 2013. – Vol. 1. – R297.

7. Guidelines for antithrombin use at ucdmc. 6/2015.

8. Edward F. Goljan (2011). Pathology. Mosby/Elsevier. Retrieved 24 August 2014. – P. 251.

9. Peripheral nerve injuries during cardiac surgery: risk factors, diagnosis, prognosis, and prevention / Sharma A. D., Parmley C. L., Sreeram G. et al. // J Thorac Cardiovasc Surg. – 1991. – Vol. 102. – P.724–9.

10. Knapik P., Cies 2la D. Incidence and prediction of permanent neurological deficits after cardiac surgery – are the existing models of prediction truly global? // Eur J Cardiothorac Surg. – 2010. – Vol. 37. – P. 717–723.

11. Recommendations for the use of antithrombin concentrates and prothrombin complex concentrates // Blood Transfus. – 2009 Oct. – Vol. 7 (4). – P. 325–334.
How to Cite
Dehtiar, V., Boichenko, O., Zhovnir, V., & Chanhli, N. (2017). The first experience of using synthetic Antithrombin-III (Athenativ) in cardiosurgical practice. Ukrainian Journal of Cardiovascular Surgery, (3 (29), 100-102.